Ana M. Metelo

569 total citations
10 papers, 419 citations indexed

About

Ana M. Metelo is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ana M. Metelo has authored 10 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Ana M. Metelo's work include Vanadium and Halogenation Chemistry (3 papers), CAR-T cell therapy research (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Ana M. Metelo is often cited by papers focused on Vanadium and Halogenation Chemistry (3 papers), CAR-T cell therapy research (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Ana M. Metelo collaborates with scholars based in Portugal, United States and Spain. Ana M. Metelo's co-authors include Othon Iliopoulos, Pilar López‐Larrubia, Rania Baker, Aria F. Olumi, Paulo A. Gameiro, Gregory Stephanopoulos, Zongwei Wang, W. Kimryn Rathmell, Alexandra Arreola and Juanjuan Yang and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Cell Metabolism.

In The Last Decade

Ana M. Metelo

10 papers receiving 408 citations

Peers

Countries citing papers authored by Ana M. Metelo

Since Specialization

Citations

This map shows the geographic impact of Ana M. Metelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana M. Metelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana M. Metelo more than expected).

Fields of papers citing papers by Ana M. Metelo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana M. Metelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana M. Metelo. The network helps show where Ana M. Metelo may publish in the future.

Co-authorship network of co-authors of Ana M. Metelo

This figure shows the co-authorship network connecting the top 25 collaborators of Ana M. Metelo. A scholar is included among the top collaborators of Ana M. Metelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana M. Metelo. Ana M. Metelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors 2022 ·Cancer Research Communications ·Ana M. Metelo, Agnieszka Jóźwik, Le Anh Luong, (unknown), Charlotte Graham, (unknown), (unknown), Alan Dunlop, (unknown), Kirsty Cuthill, Carmel Rice, Matthew Streetly, Trevor Bentley, Bijan Boldajipour, Cesar Sommer, Barbra J. Sasu, Reuben Benjamin	17
2	Metabolic effects of VO(dmpp)₂ – an ex vivo¹H-HRMAS NMR study to unveil its pharmacological properties 2019 ·New Journal of Chemistry ·Ana M. Metelo, (unknown), Pilar López‐Larrubia, M. Margarida C. A. Castro	3
3	Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups 2019 ·Blood ·Ana M. Metelo, (unknown), Agnieszka Jóźwik, Charlotte Graham, (unknown), (unknown), Alan Dunlop, Kirsty Cuthill, Carmel Rice, Matthew Streetly, Trevor Bentley, Bijan Boldajipour, Cesar Sommer, Barbra J. Sasu, Reuben Benjamin	2
4	Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies 2019 ·Blood ·Charlotte Graham, Agnieszka Jóźwik, Ruby Quartey‐Papafio, Nikolaos Ioannou, Ana M. Metelo, (unknown), Glenda J. Dickson, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, Sandra Dupouy, Farzin Farzaneh, Piers Patten, Andrea Pepper, Reuben Benjamin	4
5	Loss ofvhlin the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma 2016 ·Disease Models & Mechanisms ·(unknown), Ana M. Metelo, Caramai N. Kamei, Randall T. Peterson, Iain A. Drummond, Othon Iliopoulos	21
6	HIF2a inhibitors for the treatment of VHL disease 2015 ·Oncotarget ·Ana M. Metelo, (unknown), Othon Iliopoulos	16
7	Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model 2015 ·Journal of Clinical Investigation ·Ana M. Metelo, (unknown), Xiang Li, Youngnam N. Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan T. Shin, Anne E. Carpenter, Jing-Ruey Joanna Yeh, Randall T. Peterson, Othon Iliopoulos	38
8	In Vivo HIF-Mediated Reductive Carboxylation Is Regulated by Citrate Levels and Sensitizes VHL-Deficient Cells to Glutamine Deprivation 2013 ·Cell Metabolism ·Paulo A. Gameiro, Juanjuan Yang, Ana M. Metelo, (unknown), Rania Baker, Zongwei Wang, Alexandra Arreola, W. Kimryn Rathmell, Aria F. Olumi, Pilar López‐Larrubia, Gregory Stephanopoulos, Othon Iliopoulos	258
9	VO(dmpp)2 normalizes pre-diabetic parameters as assessed by in vivo magnetic resonance imaging and spectroscopy 2012 ·Journal of Inorganic Biochemistry ·Ana M. Metelo, (unknown), M. Margarida C. A. Castro, Pilar López‐Larrubia	29
10	Study of the antidiabetic capacity of the VO(dmpp)2 complex 2010 ·Journal of Inorganic Biochemistry ·(unknown), Ana M. Metelo, Alice Melão, (unknown), Henrique Faneca, Eugénia Carvalho, M. Margarida C. A. Castro	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact